



**TME Pharma** is a biotech company focused on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME). Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable

greater therapeutic impact. *TME Pharma's* mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival.

The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, *TME Pharma* is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results.

## Pipeline

| Indication   | Preclin.  | Ph 1/2 | Ph 2 | Ph 3 | target population US & EU <sup>2</sup> | total addressable market | next inflection points                 |
|--|---|--------|------|------|--|--------------------------|--|
| NOX-A12 + radiotherapy<br>Brain cancer / glioblastoma <sup>1</sup> |  |        |      |      | 29,000                                 | \$2.5 bn                 | Phase 1/2 BEV exp. arm read-out - 2022 |
| NOX-A12 + immunotherapy<br>Pancreatic cancer                       |  |        |      |      | 69,000                                 | \$6 bn                   | Phase 2 protocol approval in 2022      |

<sup>1</sup>: Orphan drug status US & EU; expansion arms + anti-VEGF, + anti-PD-1.

<sup>2</sup>: New cases per year.

 trial completed  trial ongoing or in preparation

## Market potential & timing


## Glioblastoma – Ground-Breaking Top Line Clinical Data

Glioblastoma is a devastating orphan brain cancer where the TME plays a significant role. Following radiotherapy (RT) treatment that kills tumor cells and destroys the local blood vessels, NOX-A12 blocks the revascularization of the

tumor area, thus preventing tumor cells from growing and proliferating again and enhances the anti-cancer immune response by increasing the number activated, proliferating cytotoxic T-cells to the tumor tissue.

| Cohort therapy                                 | tumor size reduction | partial response <sup>3</sup> |
|--|----------------------|-------------------------------|
| Standard of care historical control arm (n=20) | 25%                  | 10%                           |
| NOX-A12 + RT (n=10)                            | 90%                  | 40%                           |
| NOX-A12 + RT + Beva (n=5)                      | 100%                 | 100%                          |

<sup>3</sup>: Tumor reduction ≥ 50%.



## Clinical highlights

- Promising efficacy data in NOX-A12 monotherapy + RT, and in combination with bevacizumab.
- Mechanism of action supported by on-therapy tissue samples.
- Good safety and tolerability profile of all combinations.

## Upcoming catalysts in Q4 2022

- Data maturation of NOX-A12 + bevacizumab.
- Discussions with regulators on optimal path to approval.

|        |                       |                    |                   |
|--------|-----------------------|--------------------|-------------------|
| market | EuroNext Growth Paris | market cap         | ~ €7 M *          |
| ticker | ALTME                 | no. shares         | 1,361,094 *       |
| ISIN   | NL0015000YE1          | liquidity contract | Invest securities |

\*: As of July 27, 2022.

TME Pharma  
Max-Dohrn-Strasse 8-10  
10589 Berlin, Germany  
www.tmepharma.com

Aram Mangasarian, PhD, CEO  
Bryan Jennings, CFO  
Dr. Jarl-Ulf Jungnelius, Sr. Med Advisor